Unsubscribe
To unsubscribe, please enter your e-mail address below or send us an e-mail at unsubscribeeu@blueprintmedicines.com
Please enter a valid e-mail address
SM presents with symptoms from skin lesions to fatigue that diminish everyday living, to organ damage that can reduce survival1–3
Mast cell-mediator symptoms in SM can be unpredictable and identifying the underlying disease often takes years. SM symptoms can be triggered by aspects of everyday life, including heat, stress, exercise and food, although these triggers vary considerably and are not always representative1
Common symptoms such as skin lesions, anaphylaxis and diarrhoea should raise suspicion of SM1,2,6
Download the symptom checklist to help you recognise the symptoms or features indicative of SM
It is estimated that around 95% of ISM patients and around 50% of Advanced SM patients experience maculopapular skin lesions7*
Small monomorphic lesions often appear on the thighs or trunk of the body7
A wheal-and-flare reaction is induced by stroking lesions mechanically, e.g. with tongue spatula7
In the PRISM trial, 28% of patients with SM stated skin symptoms as their most bothersome symptom3†
Patients with Advanced SM can experience organ damage, including ascites, osteolytic lesions, liver dysfunction, weight loss, cytopenia and hypersplenism2,5
The presence of persistent non-chemotherapy-specific symptoms in patients with AHNs should prompt suspicion of SM6,8
About 33% of patients living with SM experience anaphylaxis;1‡ it is commonly triggered by hymenoptera stings or may occur as unexplained or idiopathic anaphylaxis5
At least 60% of patients living with SM experience difficulty concentrating or bothersome fatigue1‡
The unpredictable onset of acute symptoms is a main reason that patients with mast cell diseases seek support1
*As described by the expert panel review of adult-onset mastocytosis (predominantly indolent population) in the Hartmann 2016 study.7
†Based on data from the EU PRISM Patient Survey on the impact of SM (N=540).3
‡Based on data from the Mast Cell Connect Registry (N=163) in the Jennings 2018 study.1
Recognising severe and recurrent instances of the common symptoms can help raise suspicion of SM, even within a concomitant diagnosis6
Initial screening upon suspicion can guide the need for next steps or referral
Screening following referral can help confirm or rule out the diagnosis
Jennings SV, et al. Immunol Allergy Clin North Am. 2018;38(3):505–525.
Pardanani A. Am J Hematol. 2023;98(7):1097–1116.
Triggiani M, et al. Clin Exp Allergy. 2025;55(9):784–794.
van Anrooij B, et al. Allergy. 2016;71(11):1585–1593.
Gülen T, et al. J Intern Med. 2016;279(3):211–228.
Valent P, et al. J Allergy Clin Immunol Pract. 2022;10(8):1999–2012.e6.
Hartmann K, et al. J Allergy Clin Immunol. 2016;137(1):35–45.
Rets A, George TI. Int J Lab Hematol. 2025. doi: 10.1111/ijlh.70011. Online ahead of print.
Schwaab J, et al. J Allergy Clin Immunol Pract. 2020;8(9):3121–3127.e1.
Want to learn more about Systemic Mastocytosis?
Visit our Resources Page for more information.
Take me there!